- All
- Company Announcements
- Other news
- Interim
- Other Corporate Information
- Shares
- mfn-ext-nq-inside-information
- Report
- mfn-ext-nq-listing
- Corporate Information
- mfn-ci-insider
- mfn-regulatory-dcma
- mfn-ci-shareholder-announcement
Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023
BI 1820237 a novel long-acting neuropeptide Y receptor type 2 (NPY2) agonist, has been evaluated in a phase 1 clinical trial. Results to be presented today at the ECO 2023…
Gubra posts 19% CRO revenue growth in Q1 2023. Full-year 2023 outlook maintained.
Gubra, specialised in pre-clinical contract research services (CRO) and peptide-based drug discovery within metabolic and fibrotic diseases, today reported 19% revenue growth in the CRO business segment in Q1 2023…
Invitation to the presentation of Gubra’s Q1-2023 results
Gubra will host a conference call for investors, analysts and media on Thursday, May 11, 2023, at 10:00am CET. The company's Q1-2023 Trading Statement will be published on the same…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…
Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Gubra announces the end of the stabilisation period
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Stabilisation measures taken
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Major shareholder announcement
Gubra A/S, CVR no. 30514041 (the “Company” or “Gubra”) hereby announces that it has received a major shareholders' announcement pursuant to section 38 of the Danish Capital Markets Act regarding…
Completion of the offering and registration of capital increase in Gubra A/S
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
No termination or withdrawal of Gubra A/S’ initial public offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Major shareholder announcement
With reference to company announcements dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S, CVR…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities…
Gubra publishes financial calendar for 2023
With reference to company announcement dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S (the…
Stabilisation period begins
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Gubra announces the result of its initial public offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Gubra publishes prospectus and sets offer price at DKK 110 per share for its initial public offering and listing on Nasdaq Copenhagen
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Gubra announces intention to launch an Initial Public Offering on Nasdaq Copenhagen and raise capital to support its growth strategy
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION…
Collaboration with Ferring on Inflammatory Bowel Disease (IBD)
Saint Prex, Switzerland and Hørsholm, Denmark – November 15, 2022 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel…
Gubra once more awarded EY Entrepreneur Of The Year, Region Zealand.
Gubra once again wins the regional award title EY Entrepreneur of the year, Region Zealand In its justificatin, the EY committee recognizes Gubra’s development and enormous growth journey since our…
Gubra strengthens Board of Directors with two international appointments
Hørsholm, Denmark – September 20, 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election…
Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments
Hørsholm, Denmark 23 May 2022 Gubra, a leader in preclinical services within metabolic and fibrotic diseases, and with a strong pipeline of novel discovery projects, today released its 2021…
Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform
HØRSHOLM, Denmark – 10 February, 2022 Gubra ApS announced today a new research collaboration with Silence Therapeutics PLC to develop novel RNAi therapeutics for liver diseases with an unmet medical…
Gubra launches NeuroPedia – a mouse brain atlas for virtual neuroscience
Hørsholm, Denmark, January 11 2022 Quantitative 3D imaging using light sheet fluorescent microscopy is revolutionizing the way we look at pre-clinical endpoints and biodistribution. The imaging team at Gubra are…
Gubra and Bayer AG collaborate to develop next generation cardiorenal treatments
HØRSHOLM, Denmark – 20 September, 2021 Gubra ApS announced today a new research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal disease.…
Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial
HØRSHOLM, Denmark – 12 August, 2021 Recently, the first healthy volunteer was dosed with GUB002496 in a clinical phase 1 trial. GUB002496 is a drug candidate aiming for weight reduction.…
Annual results 2020: A thriving core business and razor-sharp biotech profile
Hørsholm, Denmark 28 May 2021 Gubra achieves strong growth results in its core CRO business. New models in the Kidney Space and in 3D imaging well received by the market.…
Gubra wins sustainability prize 2020
We are so proud of winning this prize. Gubra wins the EY Entrepreneur of the Year Sustainability Prize 2020. The jury recognizes Gubra for our clear attitude in CSR and active…
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra…
Gubra wins EY Entrepreneur of the Year, Region Zealand 2020
Gubra is awarded EY Entrepreneur of the Year 2020, Region Zealand for the 2nd year in a row. The digital award ceremony took place 3rd December. The jury highlights “…the…
A call for simple and comparable CSR reporting
HØRSHOLM, Denmark – May 26, 2020 Gubra sets a new standard for simple and comparable CSR reporting. In the company’s first CSR Report for 2019, Gubra proves that it is…
A year of solid financial growth, scientific breakthroughs, and strong green commitment
Hørsholm, Denmark 15 May 2020 In 2019 Gubra maintains strong financial growth based on solid results in both the biotech business and the CRO business. Gross profit increases 40% to…
Gubra is sponsor of BIKE TO WORK
HØRSHOLM, Denmark – March 9, 2020 Gubra is sponsor of this year’s Danish bike campaign BIKE TO WORK BIKE TO WORK (VI CYKLER TIL ARBEJDE) is Denmark’s big national bike…
Co-financed industrial PhD scholarship from DDA
HØRSHOLM, Denmark – March 6, 2020 Congratulations to Gubra and PhD student Mathias Bonde Møllerhøj (MSc). We just received a co-financed industrial PhD scholarship from the Danish Diabetes Academy for…
Gubra wins EY Entrepreneur of the Year
HØRSHOLM, Denmark – October 30, 2019 Tuesday evening at Ledreborg Castle took a sweeping turn upwards for Jacob Jelsing and Niels Vrang when they proudly stepped up at the podium to receive…
Gubra announces the nomination of a co-invented clinical candidate from first obesity collaboration with Boehringer Ingelheim
HØRSHOLM, Denmark – June 28, 2019 On September 7, 2017, Boehringer Ingelheim and Gubra announced a collaboration for the development of novel peptide compounds to treat obesity. In June 2019,…
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
INGELHEIM, Germany and HØRSHOLM, Denmark – May 29, 2019 Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available. New…
JDRF and Gubra join forces to develop a new glucose responsive insulin for diabetes
New York and Hørsholm, Denmark, 18 June 2018 JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such…
Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
INGELHEIM, Germany and HØRSHOLM, Denmark – September 7, 2017 Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global…
Gubra reaches third research milestone under a collaboration agreement with Sanofi
Hørsholm, August 30, 2017 Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the…
Gubra announces changes to executive management team
June 1, 2016 Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going…
Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity
Hørsholm, September 23, 2013 Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets…
Subscribe for
Company updates
전문가와 무료로 상담하세요
문의하기
Gubra
유럽 본사:
Hørsholm Kongevej 11B
2970 Hørsholm, Denmark
한국어 상담:
+45 2973 1258